Nika Pharmaceuticals: Pre-revenue, heavy related-party debt and going-concern doubts

Nika Pharmaceuticals, Inc. (PINK: NIKA)

Quick read: Nika remains a pre-revenue pharmaceutical issuer that is funding operations through related‑party advances, completing mergers and licensing deals, and investing in prospective manufacturing capacity - but faces material going‑concern risk, related‑party concentration and internal control weaknesses.

* Revenue: $- for the three months and six months ended June 30, 2025 (no sales).

* Net loss: $(18,381) for the three months ended June 30, 2025 vs. $(22,457) in Q2 2024; $(31,327) for six months 2025 vs. $(65,342) for six months 2024.

* Operating expenses (Q2 2025): Total $18,381 - General & Administrative $14,300; Professional fees $4,081 (professional fees down $10,876 vs. Q2 2024).

* Cash & current assets: Cash $15,616 and Total current assets $31,607 as of June 30, 2025 (cash up from $2,083 at 12/31/2024).

* Liabilities & related parties: Total current liabilities $284,164 - all shown as "Due to related parties." Specific related‑party amounts disclosed: $205,164 due to CEO Dimitar Slavchev Savov, $45,000 due to Nika Europe, Ltd., $34,000 due to Nika Pharmaceuticals LTD.

* Stockholders' deficit: Total $(252,557); Accumulated deficit $(8,958,938) as of June 30, 2025.

* Capital activity: Weighted average common shares outstanding 1,026,406,001; issued 35,001 shares in the Merger during the quarter; Preferred stock outstanding 15,000,000 shares.

* Cash flows: Net cash used in operating activities $(31,467) for six months ended June 30, 2025 (improved vs. $(118,261) in prior period). Financing from related parties $45,000 in six months 2025 (vs. $103,419 prior).

* Material non‑cash transactions: Preferred shares issued under Exclusive Rights Agreements valued at $2,400,000 (for TNG rights) and $600,000 (for two supplements) - total non‑cash expense $3,000,000 recorded in 2022 agreements.

* Other notable items: GMP vial line cost $957,670 contracted by Nika Europe (down payment $191,534 paid by CEO personally); building/land valued at 3,683,800 BGN (~$2,016,562) was reported in April 2024 but later the acquisition of the Bulgarian subsidiary was cancelled (August 2024) and those ownership assertions reversed.

* Controls & governance: Management concluded disclosure controls were NOT effective as of June 30, 2025; noted potential material weaknesses: lack of an audit committee and lack of separation of duties.

* Going concern: Company discloses substantial doubt about ability to continue as a going concern given accumulated deficit and no revenue.

Positive points

* Cash increased to $15,616 from $2,083 - indicates short‑term liquidity improvement.

* Operating loss narrowed year‑over‑year (six months: $(31,327) vs. $(65,342)), and professional fees decreased, suggesting some cost control.

* Business development activity: exclusive rights agreements, technology purchases, merger completed (common control), and contracted manufacturing equipment via Nika Europe - these create potential future revenue pathways if executed.

Negative / Risks

* No revenue to date - the income statement shows zero sales and recurring losses (accumulated deficit $8,958,938).

* Heavy reliance on related‑party funding and advances ($284,164 current liabilities due to related parties; CEO advances >$205,000) - concentration and potential conflicts of interest.

* Significant non‑cash preferred stock issuances tied to related parties and management (total $3,000,000 valuation recorded) - dilutive and governance red flags.

* Material uncertainty about ownership and asset transfers (acquisition and later cancellation of Bulgarian subsidiary and alleged factory/land ownership) increases execution and legal risk.

* Control weaknesses (no audit committee, inadequate separation of duties) and recent accounting firm turnover - raises reliability concerns about financial reporting.

* Going‑concern disclosure - the company will need external capital or a successful operating acquisition to survive.

Bottom line: Nika Pharmaceuticals, Inc. (PINK: NIKA) is a development‑stage, pre‑revenue issuer with active licensing and merger transactions that could create value if the company executes manufacturing and commercialization plans. Near term, performance hinges on securing third‑party capital, resolving governance and control weaknesses, and converting intellectual property and planned manufacturing capacity into actual sales. Monitor cash runway, related‑party exposure, completion/timing of GMP manufacturing capacity and any independent audits or remediation of internal control issues.